C:NYSECitigroup, Inc. Analysis
Data as of 2026-03-09 - not real-time
$106.59
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Citi is trading at $106.6, comfortably above its 200‑day SMA of $100.1 but below the 20‑day ($113.2) and 50‑day ($115.8) averages, indicating a neutral to slightly bearish short‑term bias. The 14‑day RSI of 38.6 and a bearish MACD histogram reinforce this cautious stance, while volume is trending upward, suggesting buying interest may be building. On the valuation side, the trailing P/E of 15.2 sits below the industry average of 17.4 and the forward P/E of 8.8 signals significant earnings upside; the price‑to‑book of 0.97 also places the market price under the $110 book value per share. Dividend yield remains attractive at 2.25% with a modest 33% payout ratio, supporting cash‑flow sustainability.
Fundamentally, revenue growth of 4.4% and operating margins above 25% provide a solid earnings base, and analysts collectively rate the stock as a Buy with a mean price target of $134.8, implying roughly 26% upside. Recent analyst commentary, notably JPMorgan’s raise of the target to $134 and an Overweight rating, adds confidence to the upside thesis. However, the negative operating cash flow of $‑67.6 B and a sizable debt load of $777 B warrant monitoring, especially in a rising‑rate environment. The high beta (~1.3) and 30‑day volatility near 40% flag elevated market risk, but the diversified global footprint and strong capital position temper sector‑specific concerns.
Fundamentally, revenue growth of 4.4% and operating margins above 25% provide a solid earnings base, and analysts collectively rate the stock as a Buy with a mean price target of $134.8, implying roughly 26% upside. Recent analyst commentary, notably JPMorgan’s raise of the target to $134 and an Overweight rating, adds confidence to the upside thesis. However, the negative operating cash flow of $‑67.6 B and a sizable debt load of $777 B warrant monitoring, especially in a rising‑rate environment. The high beta (~1.3) and 30‑day volatility near 40% flag elevated market risk, but the diversified global footprint and strong capital position temper sector‑specific concerns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and RSI suggest limited upside in the near term
- Increasing volume hints at potential buying pressure
- Analyst target provides ~26% upside but price is near support
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Valuation discount (PE below industry, PB <1)
- Forward earnings growth implied by low forward PE
- Attractive dividend yield and sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Diversified global banking franchise
- Strong capital base and book value above price
- Long‑term earnings stability and dividend growth potential
Key Metrics & Analysis
Financial Health
Revenue Growth4.40%
Profit Margin18.89%
P/E Ratio15.2
ROE6.83%
ROA0.58%
P/B Ratio1.0
Op. Cash Flow$-67632001024
Industry P/E17.4
Technical Analysis
TrendNeutral
RSI38.6
Support$102.01
Resistance$125.16
MA 20$113.18
MA 50$115.75
MA 200$100.08
MACDBearish
VolumeIncreasing
Fear & Greed Index100
Valuation
Target Price$134.77
Upside/Downside26.44%
GradeUndervalued
TypeBlend
Dividend Yield2.25%
Risk Assessment
Beta1.26
Volatility39.81%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.